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Abstract: Migraine is a common disabling primary headache disorder. Despite the need for 
a perfect treatment of this debilitating condition, the ideal “cure” eludes us. In 1992, the ﬁ  rst 
triptan was released in the US for use in acute migraine. Triptans are more speciﬁ  c for the 
serotonin receptor 5-hydroxy triptamine (5-HT) 1 than previously prescribed drugs, such as 
ergotamines, with fewer side effects. This was an important ﬁ  rst step in speciﬁ  c acute migraine 
therapy. Today however, triptans continue to be underutilized. There remains a concern, among 
practitioners and patients, about possible cardiovascular safety issues, despite the lack of strong 
evidence of serious adverse events. In fact, triptans now have a safe track record over more 
than a decade of use. Other perceived downfalls to use, include cost and variable efﬁ  cacy. The 
more we learn about the clinical features and pathophysiology of migraine, the closer we are to 
ﬁ  nding a satisfactory monotherapy. Until then, recognizing that mixed mechanisms underlie 
migraine symptoms, rational polytherapy can be useful. Research on the roles of serotonin, 
calcitonin gene related peptide, glutamine and N-methyl-D-aspartate in the trigeminovascular 
system holds promise for those searching for the perfect migraine headache cure.
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Introduction
Migraine is a debilitating recurring primary headache disorder. Twenty eight million 
people in the US suffer from migraine with a prevalence of 18.2% among females and 
6.5% among males (Lipton et al 2001a). Limited information about the pathophysiology 
of migraine may lead to diagnostic and therapeutic challenges, as well as delayed 
and/or partial relief, with risk of progression from a relapsing/remitting state to a 
chronic, more severe condition. Chronic daily headache is present in up to 4% of the 
US population (Lipton et al 2001b).
Although the onset is usually over the age of 12, migraine in young children is 
well recognized. In the pediatric population worldwide, the prevalence has been 
reported to be between 3–24.5% (Lipton and Bigal 2005). The mean age at onset for 
boys is 7.2 years and for girls is 10.9 years. Until puberty, boys have a slightly higher 
prevalence than girls do. In adults, migraine prevalence peaks between the ages of 
25–55: the most productive years. Migraine costs 15.5 billion dollars a year in lost 
revenue from loss of work hours and use of medical facilities (Stewart et al 1996). 
Three-fourths of adult migraineurs are women. It occurs in all races, with the highest 
prevalence in the US among Caucasians. The migraineur, suffers not only from pain 
but also lives with a diminished to poor quality of life.
Clinical presentation
Migraine is a chronic neurological disorder characterized by paroxysmal episodes of 
headache and associated symptoms typically lasting 4–72 hours (ICHD 2004). The 
migraineur reacts to normal stimuli, which may stem from a state of chronic ﬂ  uctuating Therapeutics and Clinical Risk Management 2007:3(3) 450
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neuronal hyperexcitability (Tepper et al 2001; Bussone 2004; 
Gargus 2006). Migraine phases which may overlap include 
the prodrome, aura, headache, and postdrome (Saper 1997). 
The migraine attack may be precipitated by an exogenous 
or endogenous trigger. 
The trigger mechanism, which though not well under-
stood, is most likely a cortical phenomenon. Even though 
one trigger common to that patient may induce migraine, 
often this is difﬁ  cult to pinpoint due to the multiplicity 
of events (the ﬁ  nal event being the “straw that broke the 
camel’s back”). Common exogenous triggers include expo-
sure to glare, heat, motion, raucous noise, or the ingestion 
of tyramine containing foods, alcohol, or other neuronally 
active substances. Endogenous triggers include stress; sleep 
disturbances, falling estrogen levels and others. Karli et al 
(2005) found that among 96 Turkish patients, with different 
headache types, different triggers predominated. Hunger 
and odors were more signiﬁ  cant in typical migraine with 
and without aura, and nonmigraine headaches. Some foods 
were more signiﬁ  cantly a trigger for migraine without aura 
rather than other headaches. Head and neck movements 
triggered episodic tension type headache (ETTH). Stress, 
anxiety and menstruation were relatively common triggers 
for both migraine and ETTH, but menstruation is a less 
frequently reported trigger in ETTH. Once triggered, the 
excited cortex relays the information to brainstem centers, 
which continue the process through the migraine phases. 
Clinical expression of this is variable among patients and 
from headache to headache. 
A prodrome can be present in anywhere from 10–80% 
of migraineurs (Russell et al 1996), depending on reporting 
patterns and different deﬁ  nitions. These symptoms may not 
be reported to the physician without prompting. It is not 
the same as aura and there are no validated criteria for its 
diagnosis (Tipper 2001; Evans et al 2002). In the majority 
prodrome may precede the headache phase by 1–24 hours 
but in a few can be up to 48 hours early. If it lasts for more 
than 6 hours and less than 48 hours prior to headache onset, 
it is nonevolutive prodrome (Tipper 2001; Evans and Man-
nix 2002; Kelman 2004). Symptoms tend to be vague and 
nonfocal and can be divided into systemic, neurologic and 
autonomic. Latter consist of nausea, constipation, yawning, 
ﬂ  uid retention, polyuria, feeling cold and diarrhea, whereas 
systemic symptoms usually are food cravings, anorexia, and 
feeling tired. Neurologic symptoms range from irritability, 
malaise, depression, lethargy, disinhibition, photophonopho-
bia, fatigue, and hyperactivity, or musculoskeletal symptoms 
(muscle tenderness, and stiffness) (Tipper 2001; Evans and 
Mannix 2002; Rozen 2004; Kelman 2004). Many patients 
notice mild cognitive difﬁ  culty. Appetite changes may 
include cravings for starchy or sweet foods; leading to the 
erroneous idea that chocolate is a trigger factor (Marcus 
1997). Rozen (2004) described redness of nose as prodromal 
symptom in a young woman. Recognition of the prodrome 
is important in the early treatment paradigm (Evans and 
Mannix 2002; Kelman 2004), as the attack can be aborted 
in the pre-headache phase in up to 60% of patients (Luciani 
et al 2000; Rozen 2004).
An aura is present in 15%–20% of migraineurs. In contra-
distinction to the prodrome, this is a focal phenomenon which 
can have both “positive” (extra sensations) and “negative” 
(lack of sensation) symptoms (Silberstein et al 2002). Each 
aura symptom typically lasts 5–60 minutes. Ninety nine 
percent of the migraine patients with aura experience a 
visual aura in at least some of their auras. The most common 
is the visual scintillating scotoma, which is a ﬁ  eld defect, 
circumscribed by shimmering lights (Kirchmann 2006). If 
aura consists of more than one symptom, they come in quick 
succession. Sensory and visual auras occur on one side of 
the body. Sensory phenomenon (54%), and speech/aphasic 
symptoms (32%) are the most common, though motor, 
(Thomsen et al 2004) and vertiginous symptoms (Eggers 
2006) have been described. The two most common of the 
auras, sensory and the speech, are the only ones that the 
new International Headache Society classiﬁ  cation (ICHD-II 
2004) lists. Their criteria for migraine with aura are: gradual 
development of the symptom over 4 minutes, duration should 
be less than 60 minutes, consisting of one or more reversible 
brain symptom and the headache should follow within 60 
minutes of it. When the aura occurs without an after follow-
ing headache, it is called acephalgic migraine. Although 
variation in duration can occur, prolonged or severe aura 
type symptoms should alert the physician that a neurologic 
work-up might be indicated. 
Next, in the headache phase, the pain is classically 
described as an intensely throbbing unilateral headache. It 
may begin on the face, scalp, or neck and often becomes 
holocephalic as it peaks. It is variably associated with nausea, 
vomiting, phonophobia, photophobia, and most importantly 
is worse with activity (ICHD–II 2004). Patients typically 
seek a cool, dark and quiet place; and sleep can induce head-
ache resolution. When the headache recedes, the postdrome 
phase begins, during which the person feels that they have 
just battled a storm. They feel tired, “hung-over”, and may 
have cognitive difﬁ  culties, GI symptoms, mood changes or 
weakness. The area of previous headache is now tender and Therapeutics and Clinical Risk Management 2007:3(3) 451
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hypersensitive to touch even combing the hair can become 
unbearable because of scalp sensitivity. This pain that results 
from nonnoxious stimuli to normal skin is called allodynia 
(Burstein 2000). Recently Kellman (2006) showed that 68% 
of the 827 migraineurs studied reported above mentioned 
symptoms in the post headache period. 
In 2004, the International Headache Society in col-
laboration with the American Headache Society published 
a revised classiﬁ  cation system for all types of headaches. 
Originally designed to promote common terminology and 
diagnosis for headache research studies, it has also fostered 
a better understanding of migraine symptoms and diagnosis 
for practitioners (Classiﬁ  cation and WHO ICD-10 Codes 
– IHS ICHD-II 2004).
Despite the vast number of migraine sufferers and 
disabling features of migraine, only a small percentage 
of patients see a physician. Lipton et al (2006) found that 
although half of the migraine patients, identiﬁ  ed in random 
telephone interview, had been to see a physician, one third 
had never consulted a doctor for their headaches and 21% 
had not seen one in the last year. Some do not believe they 
have migraine; others do not have conﬁ  dence in what medi-
cine has much to offer. Many with migraine instead turn to 
over-the-counter headache medications, which have proven 
efﬁ  cacious only in mild migraine. It has been shown that 
94% of patients that present to the primary care physician’s 
ofﬁ  ce with the complaint of recurrent episodic disabling 
headache are suffering from migraine or migrainous head-
ache (Newman et al 2002; Tepper et al 2004). A correct 
diagnosis on the ﬁ  rst visit with subsequent corroboration via 
headache diaries can speed the therapeutic process along.
The pathophysiology of migraine
The best treatment for any disease comes from understanding 
its pathophysiology. According to Wolff’s original vascular 
concept, the initial event of a migraine was vascular 
constriction, giving rise to aura due to focal hypoperfusion 
of the cortex. It was presumed that this was followed by a 
reactive vasodilatation, resulting in throbbing headache. 
This paradigm ﬁ  ts in very nicely with some but not all 
of the symptoms of migraine. In the latter half of the last 
century, brain perfusion studies and other data disproved 
Wolff’s theory. Currently, migraine is considered a neuro-
vascular disorder involving the trigeminovascular system 
(Welch 2003; Silberstein 2004; Goadsby 2005). The genetic 
predisposition is most certainly multifactorial, autosomal 
dominant with hundreds of different mutations (Edvinsson 
and Uddman 2005; Takeshima and Nakashima 2005). The 
paroxysmal nature of migraine suggests that it might be 
related to mutations in the calcium channel gene rendering 
neurons unstable so they react to normal environmental 
stimuli abnormally initiating the migraine attack (Bussone 
2004; Gargus 2006).
The trigger mechanism, though not well understood, 
may in many cases be related to hypersensitivity of occipital 
(Aurora et al 1998; Welch 2003), hypothalamic, and limbic 
cortex, or other cortical structures affecting parasympathetic 
pathways (Burstein and Jakubowski 2005a). The prodrome 
phase of the migraine is possibility related to hypothalamic 
activation/dysfunction (Tipper 2001; Benjamin et al 2004), 
and hyperexcitability of central pain processing (Burstein 
2000) with, possibly, increased dopaminergic activity 
(Peroutka 1977). 
In the 1940’s Brazilian physiologist, Aristides Leão 
(1944), showed that application of potassium chloride 
directly to rat cerebral cortex caused a depression of cortical 
activity that gradually spread to the adjacent cortex at the rate 
of 3–4 mm/minute. A few years prior Karl S. Lashley (1941), 
a neurologist, documented the rate of spread of his own 
visual aura and postulated that this must be due to a spread-
ing cortical phenomenon. The two observations were linked 
and cortical spreading depression (CSD) has been accepted 
as possible major underlying mechanism of migraine aura 
(Dalkara et al 2006). Hadjikhani et al (2001) used functional 
magnetic resonance imaging (fMRI) to show blood oxygen-
ation dependent signal changes in the cortex of patients with 
migraine aura occurring from occipital cortex frontally at the 
rate of 3–5 mm/min in conjunction with decreased visual 
acuity. CSD as a generator of visual aura has also been sup-
ported with transcranial magnetic stimulation (Aurora 1998). 
Studies show that CSD in migraine is preceded by a brief 
phase of cortical spreading excitation. This helps to explain 
why neuromodulators, which inhibit depolarization, decrease 
the migraine aura frequency (Silberstein 2004).
The trigeminal system innervates the meninges, and pro-
vides sensory innervation to the intracranial vessels. The neu-
ronal bodies of these sensory neurons lie within the trigeminal 
ganglia. Upon stimulation impulses travel antidromically to 
dural tissue causing dilatation of the meningeal blood ves-
sels and local release of neuropeptides – Substance P, nitric 
oxide, vasoactive intestinal polypeptide, 5-HT, Neurokinin A 
and CGRP, a potent vasodilator. This leads to plasma protein 
extravasation and initiation of sterile neurogenic inﬂ  amma-
tion. While it is an important factor in causing headache pain, 
it is not clear if it is by itself sufﬁ  cient or other stimulatory 
factors are required to be part of the process leading to pain Therapeutics and Clinical Risk Management 2007:3(3) 452
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in the head (Welch 2003; Goadsby 2005; Edvinsson and 
Uddman 2005). The nociceptive activation process leads to 
peripheral sensitization, with further release of excitatory 
neurotransmitters mediated by opening of sodium channels 
(Arulmani et al 2004; Edvinson 2004). 
Neurogenic inﬂ  ammation in the meninges causes reactive 
impulses from the meningeal ﬁ  rst order trigeminal neurons to 
travel orthodromically back to the brainstem to the trigemi-
nal nucleus caudalis (TNC). From the TNC, second order 
neurons promote stimulation of central structures responsible 
for prolongation and wind up of the migraine process. From 
the TNC the information travels: 
1)  Through second order neuron central projections via the 
thalamus to cortical third order neurons for central pain 
perception; 
2) Through parasympathetic pathways (hypothalamus- 
superior salivatory nucleus – sphenopalatine ganglion) 
to give rise to increased secretions in the sinus cavities 
and tear ducts; and 
3)  Through the upper cervical ﬁ  bers mediating pain from 
the back of the head and upper neck area (Ramadan 2005; 
Goadsby 2005).
Central Sensitization perpetuates the migraine after the 
initial onset. It involves wide dynamic range neurons at the 
TNC level to ventral postero-medial nucleus of thalamus and 
cortex. Once started, it maintains itself without any extrane-
ous input. More than 4/5 of migraine sufferers experience 
central sensitization as evidenced by prolonged allodynia, 
which is associated with release of excitatory neurotransmit-
ters in central nervous system (CNS). Thus, there is exces-
sive NMDA receptor activation. Normally it is modulated 
by brainstem pain modulation centers, (peri-aqueductal gray 
(PAG) and locus ceruleus) but in migraine and other pain 
states, these centers may be dysfunctional (Welch 2001; 
Silberstein 2004).
Serotonin is an important neurotransmitter in migraine. It 
has been shown that during a migraine attack the excretion of 
5-hydroxyindole-acetic-acid increases. Serotonin itself, when 
given slowly intravenously (IV), can abort a migraine attack. 
Since it is widely present in the body, with both stimulatory and 
inhibitory effects, there are many side effects of unadulterated 
5-HT so it is not used for migraine treatment. Fortunately, the 
more selective 5-HT agonists are better tolerated.
There are seven different subsets of 5-HT receptors
(1–7), 
some inhibitory and others excitatory. The receptors for 
5-HT
1–4 and 5 HT have been identiﬁ  ed. 5-HT
1 has ﬁ  ve sub-
groups: A, B, D, E and F. Triptans are relatively selective 
agonists at the inhibitory 5-HT
1B/1D receptor sites, thereby 
inhibiting release of vasoactive peptides. Trigeminal nerve 
endings also have 5-HT 
1D/1F receptors endings, which inhibit 
the release of CGRP and substance P. 5-HT
1B receptors are 
present post-synaptically in cerebral blood vessels and their 
stimulation leads to vasoconstriction. 5-HT
1F/1B
 receptors are 
known to inhibit the release of acetylcholine, noradrenalin, 
and serotonin (Villalón 2003; Silberstein 2004).
Central modulation of pain
During the last decade, the central modulation of pain in 
migraine has been of major interest. Brainstem centers such 
as the PAG normally receive and modulate sensory neuronal 
input. In migraine and other pain states, these centers are 
dysfunctional resulting in excessive thalamic activity lead-
ing to increased pain perception. The initiating trigger in the 
brainstem may be linked to a familial channelopathy (Kors 
2003; Gargus 2006). In patients experiencing migraine with 
aura, a positron emission tomography study demonstrated 
activation of the dorsal midbrain, including PAG and pons 
near the locus ceruleus. These areas were activated immedi-
ately after successful treatment of pain (Weiller et al 1995). 
It was subsequently shown in an fMRI study that the PAG 
was not activated when the subject was paying attention to 
the pain stimulus and there was high intensity pain, but was 
activated during distraction from the pain stimulus when the 
perception of pain was lessened. The conclusion was that the 
PAG induces analgesia (Silberstein 2004).
An excitatory modulatory mechanism in migraine is 
via the neurotransmitter glutamate. Migraineurs have CNS 
hyperexcitability involving overactivity of excitatory amino 
acids, such as glutamate and aspartate. Levels of these 
neurochemicals have been found in the cerebrospinal ﬂ  uid 
and plasma of migraineurs. Their presence is associated with 
hyperalgesia mediated by peripheral and central sensitization 
(Ramadan 2005). Glutamate action is mediated through both 
NMDA and non-NMDA receptors; the latter include kainate 
and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) receptors. Studies on rats show these receptors 
mediate the relay of impulses from peripheral trigemino-
vascular neurons and spinal cord nociceptive transmission. 
For example, kainate (KA) injections cause hyperalgesia, 
which can be reduced by the administration of KA receptor 
antagonists (Ta et al 2000). Some KA receptors are effective 
in preventing dural plasma protein extravasation. 
Two other modulatory mechanisms are worth mentioning, 
NMDA antagonists (memantine and MK-801) and 
non-NMDA antagonists (CNQX and NBQX). They block 
c-fos expression in the TNC in migraine animal models, Therapeutics and Clinical Risk Management 2007:3(3) 453
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following superior sagittal sinus stimulation. Ketamine, a 
nonselective NMDA antagonist, has also shown efﬁ  cacy in 
the treatment of migraine with aura and other chronic pain 
states (Kaube et al 2000). Its use in clinical practice is currently 
limited due to hallucinatory side effects. In the future NMDA 
antagonists may play a larger role in migraine treatment.
The role of inﬂ  ammation
Neurogenic inflammation occurs in migraine, although 
it is not the usual “wheal and ﬂ  air” type of inﬂ  ammatory 
response. Nonsteroidal anti-inﬂ  ammatory drugs, (NSAIDs) 
alleviate inﬂ  ammation and this appears to be same effect 
in migraine. The beneﬁ  t of NSAIDs in migraine could well 
be a nonspeciﬁ  c analgesic effect. The mechanism for this 
might involve decreased release of inﬂ  ammatory proteins, 
which decrease activation of sensory neurons, by reducing 
free radicals, which decreases nociceptor activation. Lastly, 
by blocking prostanoid receptors or prostaglandin synthesis 
which limits the inﬂ  ammatory pain response (Waeber and 
Moskowitz 2005).
Treatment of acute migraine
Once the diagnosis of migraine has been established, an 
explanation of the neurologic condition to the patient and 
family is helpful in establishing the patient’s conﬁ  dence in 
the diagnosis and management approaches. During this time, 
patients should be asked about their goals, to help bring any 
unreasonable expectations out into the open. For instance, 
complete freedom from headache may not be attainable, and 
they need to be aware of the present limitations. The patient 
is then presented with a plan that helps empower him/her 
to participate in the management of the headaches. Passive, 
helpless behavior is discouraged. Patients should know what 
they should do for their next migraine attack including res-
cue therapy if needed. To facilitate ongoing communication 
and determining triggers, a headache and medication diary 
might be useful (Loder 2001; Rothrock 2006). Avoidance of 
over use of acute medications to prevent rebound headache 
or transformed migraines is emphasized. The goal is to im-
prove pain control, quality of life, and daily function through 
appropriate treatment (Adelman and Adelman 2001).
The details of dealing with prophylactic treatment for mi-
graineurs with two or more days of moderately severe to severe 
headaches per week will not be detailed here. That is a chapter in 
itself. Sufﬁ  ce it to say that patients who have two or more days 
of moderately severe to severe headaches per week, should be 
prescribed prophylactic medications, taking into account co-
morbidities and pregnancy risk. 
The US Headache Consortium published its recommen-
dations for the treatment of migraine in 2000 (Silberstein 
2000). Acute treatment is divided into migraine-speciﬁ  c and 
nonspeciﬁ  c therapy. Nonspeciﬁ  c therapy is further divided 
into pharmacological and nonpharmacological modalities, 
as shown below.
1. Speciﬁ  c migraine treatment 
 a.  Triptans 
  b. Ergot and its derivatives
2. Nonspeciﬁ  c pharmacological treatment 
 a.  Antiemetics
  b. NSAIDs and nonnarcotic analgesics
  c. Narcotics – Opiate analgesics
3. Miscellaneous  medications: 
  a. Steroids, isometheptene, lidocaine intranasal (IN), 
  b. valproic acid IV 
4.  Nonpharmacological treatment 
 a.  Biofeedback
  b. Visual imagery (quite useful in children)
 c.  Icepack
  d. Relaxation therapy
  e. Yoga, meditation
Triptans
Ideally, acute treatment of migraine should work rapidly, 
with few side effects, be cost effective and get the patient 
functional as soon as possible. The triptans, selective serotonin 
5-HT
1B/1D agonists, are the closest drugs we have to the ideal 
drug. Sumatriptan (SUM), the ﬁ  rst triptan to be released in the 
US, was followed by six more releases within a decade. These 
include naratriptan (NAR), zolmitriptan (ZOM), rizatriptan 
(RIZ), almotriptan (ALM), eletriptan (ELE) and frovatriptan 
(FRO). While they all mainly target 5-HT
1 receptors, there are 
some differences in efﬁ  cacy and tolerability as shown by meta-
analysis (Ferrari 2002). Triptans constrict the dilated meningeal 
arteries through stimulation of 5-HT
1B receptors on the blood 
vessel wall. They also inhibit neurotransmitter release and noci-
ceptive transmission by stimulating 5-HT
1D receptors on central 
and peripheral trigeminal sensory nerves. They are unable to 
block ongoing sensitization in the second order trigeminovas-
cular neurons. Therefore, triptans should be used early in the 
headache before central sensitization has occurred and allodynia 
has set in (Burstein and Jakubowski 2005b).
Table 1 shows results of the meta-analysis comparing the 
different triptans to SUM 100 mg as an arbitrary standard 
(Ferrari 2001). In practice, responses vary from patient to 
patient. If one triptan does not work despite taking it early and 
in adequate doses, then a trial of a 2nd triptan is warranted. Therapeutics and Clinical Risk Management 2007:3(3) 454
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Factors that affect the treatment of a migraine attack 
include the presence of chronic or medication overuse 
headache, fast onset migraine, or prolonged migraine. 
Medication overuse headache may not respond to acute 
treatment until the patient has withdrawn from the 
dependence-producing substance. Fast onset migraine 
may require intranasal administration of SUM or ZOM 
or subcutaneous (SQ) SUM. Menstrual migraine patients 
may need to start medicating a day before expected 
headache as “mini-prophylaxis” with NAR, SUM or FRO 
tablets (Mannix 2005).
Oral triptan doses are titrated according to efﬁ  cacy and 
side effects. Until recently, SQ SUM was available only in 
a 6 mg dose, but a recent clinical research showed that a 
3 mg dose was comparable in efﬁ  cacy with superior toler-
ability (Landy et al 2005). Since April 2006, a 4 mg SQ 
dose is available. Although studies have been published on 
patients less than 18 years of age showing efﬁ  cacy and safety 
(Damen 2005), the triptans are currently not FDA approved 
for this age group. It is disturbing that despite the availability 
of effective drugs, less than 50% of migraineurs in the US 
receive prescription medicine for their headache as of 1999, 
according to the American Migraine Study II (Lipton et al 
2001b). Although it is possible that the current percentage 
of triptan users has increased in the last six years, but there 
are no more recent studies from the US. The same situation 
exists around the world (Dowson 2003; Morillo et al 2005). 
This is partly due to misunderstanding of the disease by 
the public and misdiagnosis by physicians. The perceived 
potential for coronary vasoconstriction has also limited 
prescribing practices. Patients who experience noncoronary 
chest pain may be unduly wary of ever taking a triptan again. 
The Triptan Cardiovascular Safety Expert Panel convened 
in 2002 and concluded that it is safe to prescribe triptans 
in patients with no known coronary artery disease (Dodick 
et al 2004). The origin of the transient chest discomfort from 
triptans is unknown. It is not attributed to cardiac ischemia 
and is without clinical sequelae. A study done involving 75 
patients with known coronary artery disease revealed no 
clinically signiﬁ  cant electrocardio graphic ischemic changes 
or arrhythmias after FRO 2.5 mg administration for migraine 
(Elkind et al 2004).
CNS side effects such as mild sedation, dizziness or 
cognitive problems can occur depending on lipophilicity and 
active metabolites. Landy and colleagues found that FRO, 
RIZ, ZOM and ELE have a higher CNS side effect proﬁ  le, 
whereas SUM, NAR and ALM are better tolerated (Dodick 
and Martin 2004).
Concerning teratogenicity, a study published in 2004 
found the same incidence (3–5%) of birth defects in babies 
born to mothers who took SUM during pregnancy as in 
babies born to unexposed mothers (Hilaire et al 2004).
Ergots/ergot derivatives
Ergotamine and ergotamine-caffeine combination pills 
still play a role in the acute treatment of migraine in those 
patients who do not respond adequately to triptan therapy. 
Ergotamine has more side effects (nausea, vomiting, 
peripheral and coronary vasoconstriction) due to its 
relatively nonselective adherence to serotonin, dopamine 
and adrenergic receptors (Villalón et al 2003). Dihydroer-
gotamine (DHE) is a long lasting potent anti-migraine drug 
that can be given parenterally as SQ, intramuscular (IM), 
IV, or IN routes, for a severe migraine attack. Pretreatment 
with an anti-emetic might be necessary. Its venous vascular 
effects are more potent than arterial, but it should be avoided 
Table 1 Triptan comparison compared to 100 mgs of sumatriptan. Copyright © 2002. Reproduced with permission from Ferrari MD, 
Goadsby PJ, Roon KI, et al 2002. Triptans (serotonin 5-HT1B/D agonists) in migraine: detailed results and methods of a meta-analysis of 
53 trials. Cephalalgia, 22:633–58.
  Initial 2 h  Sustained  Consistency  Tolerability 
 Relief  Pain  relief 
Sumatriptan 50 mgs  =  =  =/−  =
Sumatriptan 25 mgs  =  =/−  −  +
Zolmitriptan 2.5 mgs  =  =  =  =
Zolmitriptan 5.0 mgs  =  =  =  =
Naratriptan 2.5 mgs  −  −  −  =
Rizatriptan 5 mgs  =  =  =  =
Eletriptan 20 mgs  −  −  −  =
Eletriptan 40 mgs  =/+  =/+  −  =
Eletriptan 80 mgs  +  +  =  −
Almotriptan 12.5 mgs  =  +  +  ++Therapeutics and Clinical Risk Management 2007:3(3) 455
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in patients with known cardiovascular and peripheral vas-
cular disease (Silberstein 2000).
Nonspeciﬁ  c pharmacological treatment
This is used, either in addition to selective acute migraine 
therapy or as a rescue medication, in those patients whose 
headache continues despite adequate and prompt triptan 
therapy. The patients are to limit its use to 2 days per week, 
as a rule, to avoid medication overuse headache. Potential 
agents may include:
1.  Antiemetics
  a. Chlorpromazine – IV/IM 
  b. Prochlorperazine – IV/IM/Per Rectum (PR) 
  c.   Metoclopramide – IV/IM/PR – IM/PR routes have 
shown inconsistent evidence for efﬁ  cacy but may help 
with gastric paresis, which occurs during migraine, thus 
improving absorption of other oral medications. It is 
also used IV with DHE to counteract nausea.
2.  NSAIDs and nonnarcotic analgesics
  a. Ketorolac IM, IV 
  b.  Oral NSAIDs: aspirin, naproxen, diclofenac, ibuprofen 
etc are all beneﬁ  cial in mild migraine (Diener et al 
2004; Lipton 2005).
  c. Combination analgesics
    i.   Acetaminophen, aspirin, caffeine (mild migraine)
    ii.    Butalbital, ASA, caffeine – has shown inconsistent 
evidence for efﬁ  cacy in migraine, mainly studied in 
tension-type headache.
    iii.   Isometheptene mucate, acetaminophen, dichloral-
phenazone
3.   Opiate analgesics – to be used judiciously by experienced 
physicians, primarily as a ‘reserve’ medication, for acute 
severe attacks not responsive to selective abortive agents. 
This can prevent overuse of ER services in patients with 
difﬁ  cult to control migraine pain.
  a. Butorphanol nasal spray 
  b.   Acetaminophen with codeine, hydrocodone, hydro-
morphone
  c. Oral transmucosal fentanyl citrate
4. Nonopiate  analgesics
  a.   Tramadol – a synthetic analog of codeine, which can 
cause respiratory depression and has a potential for abuse, 
even though this is comparatively less than traditional 
opioid drugs
  b.   Tizanidine – centrally acting muscle relaxant with 
alpha 2- adrenergic receptor activity
5. Miscellaneous  medications
  a. Steroids (infrequent use)
    i.  Methylprednisolone dose pack
    ii. Dexamethasone (maximum 4 tabs per month)
  b.   Lidocaine IN – probably more useful in cluster head-
ache
  c. Valproic acid IV
  d. Propofol IV
Use of a preventive medication 
as an acute therapy
There have been times when a patient has told one of us 
that they obtain beneﬁ  t from taking a dose of their preven-
tive medication acutely, outside of the prescribed usage 
parameters. The usual medications involved are amitrip-
tyline, cyproheptadine, and propranolol. When valproic 
acid became available in a parenteral form, this treatment 
was studied for severe acute migraine (Stillman et al 2004; 
Leniger et al 2005). The reported effective dose for one 
administration is 500 mg given as a bolus over 15 minutes 
to 30 minutes (Schwartz 2002; Reiter 2005).
Opioid analgesics
The use of opiates is restricted to patients who are un- 
responsive to migraine speciﬁ  c therapies and require frequent 
emergency room (ER) visits to abort their migraine. The 
judicious use of opiates can markedly reduce cost and time 
as well as increase the patient’s sense of self-control in such 
cases. Opiate dependence and addiction must be screened 
for before choosing this option for the patient. Its use is best 
left for the specialists in pain and headache management. 
Synthetic opioid analogs, like tramadol, are comparatively 
safer due to lower afﬁ  nity for opioid receptors. Therefore, 
they have less potential for abuse or respiratory depression 
but these problems can still occur. It is recommended that 
these medications also be used with the same care as opioids 
(Cicero et al 1999; Grond 2004; Keskinbora and Aydinli 
2006). 
Nonoral opioid medications are especially helpful in 
patients who are vomiting too much to keep pills down. Butor-
phanol nasal spray’s efﬁ  cacy has been proven (Loder 2005). 
Most practitioners limit prescriptions to one unit (8–10 sprays) 
per month. Landy (2004) has documented the successful use 
of oral fentanyl lozenges in refractory migraine.
Combination speciﬁ  c/nonspeciﬁ  c 
pharmacological treatment
In response, to the recent trend in clinical practice towards 
combination therapy, several studies have been reported. Therapeutics and Clinical Risk Management 2007:3(3) 456
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A Brazilian researcher, AV Krymchantowski, studied 45 
patients in an open-label randomized protocol, using a 
combination of RIZ plus the COX-2 inhibitor rofecoxib (RO) 
or the NSAID tofenamic acid (TA). Results showed a supe-
rior pain-free response at 2 hours with RIZ + RO (62.9%) 
and RIZ + TA (40.6%) compared with RIZ alone (37.9%) 
and a better recurrence rate as well (Krymchantowski and 
Bigal 2004). Smith et al and Wargin et al found superior 
efﬁ  cacy of SUM + Naproxen in two separate trials presented 
at the 2005 American Academy of Neurology (AAN) an-
nual meeting. This combination is being considered for FDA 
approval to be released by Glaxo Smith Kline under the trade 
name Trexima.
Dr. Krymchantowski also showed efficacy of the 
combination of RIZ and trimebutine, an opioid derivative 
at the 2005 AAN annual meeting. This chemical binds 
only to the receptors of the Meissner and Auerbach plexi in 
the gastrointestinal tract and decreases gastroparesis. The 
combination proved more effective than either compound 
alone in achieving freedom from nausea, photophobia, and 
pain at 1 hour and 2 hours.
Migraine pain travels to the back of the head via the 
C2 pathway. A retrospective study of headache patients 
in an ER setting showed that bupivicaine injected into 
the lower cervical paraspinal muscles was effective in 
providing complete pain relief in 65.9% and partial relief 
in 18.6% (Mellick and Mellick 2004). Occipital nerve 
blockade has also been used with some success. Greater 
occipital nerve blocks and trigger point injections are 
reported to reduce allodynia and pain in migraine patients 
(Ashkenazi and Young 2005).
Nonspeciﬁ  c nonpharmacological 
treatment
Psychophysiologic management (“biofeedback”), self-
relaxation, trigger point massage, acupuncture and visual 
imagery are some of the current methods in use to help 
migraine patients. An interesting observation led M. Friedman, 
DDS, to develop a cooling device for migraineurs. He observed 
that in the majority of his migraine patients the laterality and 
intensity of the intraoral tenderness in the maxillary area, was 
very, closely related to the laterality and severity of their head 
pain. A cooling device, was developed, which was found to 
be superior in efﬁ  cacy to oral SUM 50 mg and placebo in a 
double-blinded randomized placebo controlled study. Twenty-
four hours later, there was some recurrence with SUM treated 
group but none with intraoral chilling and the side effects were 
more frequent in the SUM treated group (Friedman 2001). 
Many studies demonstrating the effectiveness of a 
variety of nonpharmacological modalities have been 
reviewed over the years. Although definite proof of 
effectiveness through traditional scientific method may 
be lacking in some instances, they deserve mention due 
to popularity in some patient groups. Many of these pro-
phylactic treatment modalities, though generally used for 
prophylaxis of migraine, can benefit patients during their 
acute migraine attacks. These consist of applying localized 
pressure on temporal artery (Drummond and Lance 1983), 
cryotherapy (Robbins 1989; Silberstein 1993; Friedmann 
2001), punctate transcutaneous electric nerve stimula-
tion (Heydenreich 1988), acupuncture points used were for 
gallbladder/large intestine/liver (Melchart et al 2003) or 
in the ear (Romoli et al 2005), relaxation techniques like 
visual imagery and progressive muscular relaxation prob-
ably for slowly evolving migraine (Pryse-Phillips et al 
1998), and biofeedback used mostly in pregnant patients 
(Silberstein 1993; Pfaffenrath and Rehm 1998). These are 
of special importance in patients who do not wish to use 
medications, in pregnant patients and for those patients 
in whom triptans are contraindicated.
In search of the ideal antimigraine drug
Although the identification of the triptans as migraine-
specific therapy has revolutionized migraine manage-
ment, they are not the panacea we once thought they 
were. The potential side effects, recurrence rate (about 
1/3), response rate (60%–70%) and contraindications limit 
their universal use. Therefore, investigators are exploring 
new migraine targets at initiation, progression and per-
petuation of the attack. Among the 5-HT
1
 receptors, the 
1D and 1F ligands have no effect on the cardiovascular 
system. Two products recently evaluated (LYT334370-
109291 and PNU-142633), are highly selective agonists 
for 5-HT
1D
 receptors. They both inhibit the extravasation 
of plasma proteins in the dura as shown in animal stud-
ies, but have not been shown to possess vasoconstrictive 
effects. Unfortunately, these agents have not been clini-
cally effective unless used at doses that also effect 5HT
1B
 
receptors, thereby negating the selectivity of the drug in 
vivo (Villalon et al 2003).
The 5-HT
3
-receptor is a ligand-gated channel, present 
in the CNS, peripheral nervous system and other cells. 
It is known to be involved in pathological processes in 
which there is increased release of serotonin. It modu-
lates the release of neurotransmitters, and neuropeptides 
and affects regulatory functions, thus its antagonists Therapeutics and Clinical Risk Management 2007:3(3) 457
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have shown clinical efficacy in studies for controlling 
vomiting, anxiety, chronic fatigue and pain in migraine, 
fibromyalgia and rheumatic disease (Farber 2004). Stud-
ies are ongoing with the 5-HT
7
 receptor agonists testing 
their potential for treating migraine.
Calcitonin gene related peptide 
(CGRP)
Currently CGRP1 antagonists hold promise as new antimi-
graine drugs. Two recently introduced are: BIBN4096BS 
and Compound 1. BIBN4096BS was tested in the marmoset 
trigeminal ganglion and found to inhibit vasodilatation. 
Other experiments support its possible role as an anti-
nociceptor mediator in migraine. Compound 1 has similar 
properties but is less potent than BIBN4096BS in human 
tissues. A third smaller CGRP antagonistic molecule is 
SB-273779. It has similar properties as the other two but 
may have greater value for the study of migraine and CGRP 
activity in animal models. 
The efﬁ  cacy of BIBN4096BS has been tested in humans 
in two studies published in 2004. In the ﬁ  rst, the safety, 
tolerability and pharmaco-kinetics of BIBN4096BS were 
tested in healthy volunteers. After a single IV administra-
tion of gradually increasing dose, most of the adverse events 
occurred at the highest administered dose (10 mg) and were 
relatively mild and transient. (Iovino et al 2004) In another 
controlled study, moderate or severe headache was treated 
with 2.5 mg of BIBN4096BS IV vs. placebo. The end-point 
of pain reduction within 2 hours to mild or no pain was 
achieved in 66% of BIBN4096BS treated patients vs. 27% 
of the placebo group (Doggrell 2004). In clinical practice, 
its potential use will be limited to settings appropriate for 
IV administration.
The glutaminergic system
Among other avenues for migraine treatment, attention is 
being given to blockade of central and peripheral sensitiza-
tion, which can be done by modulation of the glutaminergic 
system. One of these is an ampakine-KA receptor antagonist, 
which blocks signals from these receptors without constrict-
ing blood vessels, thereby inhibiting central sensitization. 
Phase I trials are underway. 
Another AMPA-KA receptor antagonist named 
LY293558 was recently reported by Sang et al (2004) to be 
efﬁ  cacious in treating migraine. A randomized triple-blind, 
parallel group, double dummy, multi-center trial tested 
LY293558 vs. SUM SC vs. placebo for one acute headache 
in forty-ﬁ  ve patients including women of childbearing age. 
They were given LY293558 IV + placebo SC, SUM SC + 
placebo IV or placebo IV + SC within 8 hours of migraine 
onset. The pain free rate at 2 hours for LY293558 was 54%, 
for SUM it was 60% and for placebo, 6%. Three of the 
patients who responded to treatment had recurrence: one 
after SUM and two following placebo. Fifteen percent of the 
LY293558 group had side effects, 53% of the SUM group 
and 31% of the placebo group. 
New routes of administration
There are some devices in phase I trials, which look promis-
ing. Alexza Molecular Delivery Corp. developed a device, 
called Staccato, for faster delivery of drugs via inhalation. A 
heating device turns the drug into a mist of micro-particles 
with rapid uptake from the lungs. Phase I clinical trials using 
prochlorperazine have been promising. Vyteris, another com-
pany, is working on a transdermal delivery system, which 
includes a low voltage electrical current to help release SUM 
into the dermal blood vessels. An initial bolus is followed 
by a sustained release of the drug. Phase I trials with SUM 
have been positive. 
Novartis is developing DHE in a powder form for nasal 
use. Phase I trials have shown the powder works faster with a 
longer duration of action than the current spray formulation. 
Another device is being investigated which will soon start 
phase II investigation. This machine sends pressurized carbon 
dioxide up one nostril and out the other. The gas in not inhaled, 
but after permeating through the nasal mucosa forms carbonic 
acid, which apparently prevents nociceptor stimulation. It is 
effective primarily in mild to moderate migraine.
Conclusion
This review emphasizes the practical treatment of migraine as 
well as the progress that has been made in deﬁ  ning migraine 
pathophysiology and in developing new speciﬁ  c therapies. There 
is room for better efﬁ  cacy and tolerability. It appears that the 
pharmaceutical and bioengineering industries, in recognition of 
the large market of migraine sufferers, is working towards newer 
and better approaches for affective interventions.
Financial disclosure
The authors declare that they have not received any ﬁ  nancial 
support from any source for producing this manuscript.
Acknowledgment
The authors thank Roger Kelley, MD for reviewing this 
manuscript and his help and guidance in so many other Therapeutics and Clinical Risk Management 2007:3(3) 458
Kalra and Elliot
areas in relation to this manuscript. We would also like 
to acknowledge Mr. I. Kalra, for his help in preparing 
the manuscript.
References
Adelman JU, Adelman RD. 2001. Current options for the prevention and 
treatment of migraine. Clin Ther, 23:772–88.
Amery WK, Waelkens J. 1983. Prevention of the last chance: an alternative 
pharmacologic treatment of migraine. Headache, 23:37–8.
Arulmani U, MaassenVanDenBrink A, Villalón CM, et al. 2004. Calcitonin 
gene-related peptide and its role in migraine pathophysiology. European 
Journ Pharm, 500:315–30.
Ashkenazi A, Young WB. 2005. The effects of greater occipital nerve block 
and trigger point injection on brush allodynia and pain in migraine. 
Headache, 45:350–4.
Aurora SK, Ahmad BK, Welch KMA, et al. 1998. Transcranial magnetic 
stimulation conﬁ  rms hyperexcitability of occipital cortex in migraine. 
Neurology, 50:1111–14.
Benjamin L, Levy MJ, Lasalandra MP, et al. 2004. Hypothalamic activation 
after stimulation of the superior sagittal sinus in the cat: a Fos study. 
Neurobiol Dis, 16:500–5.
Burstein R, Yarnitsky D, Goor-Aryeh I, et al. 2000. An association between 
migraine and cutaneous allodynia. Ann Neurol, 47:614–24.
Burstein R, Jakubowski M. 2005a. Unitary hypothesis for multiple triggers 
of the pain and strain of migraine. J Comp Neurol, 493:9–14.
Burstein R, Jakubowski M. 2005b. Implications of multimechanism therapy: 
when to treat? Neurology, 64(Suppl.2):S16–20
Bussone G. 2004. Pathophysiology of migraine. Neurol Sci, 25(Suppl. 3):
S239–S241.
Cicero TJ, Adams EH, Geller A, et al. 1999. A post marketing surveillance 
program to monitor Ultram® (tramadol hydrochloride) abuse in the 
United States. Drug Alcohol Depend, 57:7–22.
Classiﬁ  cation and WHO ICD-10 Codes – IHS ICHD-II. 2004. Cephalalgia, 
24:1–16
Dalkara T, Zervas NT, Moskowitz MA. 2006. From spreading depression to 
the trigeminovascular system. Neurol Sci, 27(Suppl. 2):S86–S90.
Damen L, Bruijn JK, Verhagen AP, et al. 2005. Symptomatic Treatment 
of Migraine in Children: A Systematic Review OF Medication Trials. 
Pediatrics, 116:e295–302.
Diener HC, Bussone, de Liano H, et al. 2004. Placebo-controlled comparison 
of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the 
treatment of migraine attacks. Cephalalgia, 24:947–54
Dodick DW, Lipton RB, Martin V, et al. 2004. Consensus statement: car-
diovascular safety proﬁ  le of triptans (5-HT1B/D agonists) in the acute 
treatment of migraine. Headache, 44:414–25.
Dodick DW, Martin VT, Smith T, et al. 2004. Cardiovascular tolerability 
and safety of triptans: a review of clinical data. Headache, 44 (Suppl 
1):S20–30. 
Dodick DW, Martin VT. 2004. Triptans and CNS side effects: pharmaco-
kinetic and metabolic mechanisms. Cephalalgia, 24:417–24
Doggrell SA. 2004. New drugs for the prevention and treatment of 
migraine: topiramate and BIBN 4096 BS. Expert Opin Pharmacother, 
5:1837–40
Dowson AJ. 2003. Analysis of the Patients Attending a Specialist UK 
Headache Clinic over a 3-Year Period. Headache, 43:14–18.
Drummond P, Lance JW. 1983. External vascular changes and the source 
of pain in the migraine headache. Ann Neurol, 13:32–37.
Edvinson L. 2004. Blockade of CGRP receptors in the intracranial vas-
culature: a new target in the treatment of headache. Cephalalgia, 
24:611–22.
Edvinson L, Uddman R. 2005. Neurobiology in primary headaches. Brain 
Res Rev, 48:438–56.
Eggers SD. 2006. Migraine-related vertigo: diagnosis and treatment. Curr 
Neurol Neurosci Rep, 6:106–15.
Elkind AH, Satin LZ, Nila A, et al. 2004. Frovatriptan use in migraineurs 
with or at high risk of coronary artery disease. Headache, 44:403–10.
Evans RW, Mannix LK. 2002. Triptans for migraine prodrome. Headache, 
42:83–84.
Farber L, Haus U, Spath M, et al. 2004. Physiology and pathophysiology of 
the 5-HT3 receptor. Scand J Rheumatol Suppl, 119:2–8.
Ferrari M, Krista IR, Lipton R, et al. 2001. Oral triptans (serotonin 
5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 
trials. Lancet, 358:1668–75.
Ferrari MD, Goadsby PJ, Roon KI, et al. 2002. Triptans (serotonin 5-HT1B/D 
agonists) in migraine: detailed results and methods of a meta-analysis 
of 53 trials. Cephalalgia, 22:633–58.
Friedmann MH, Peterson SJ, Behar CF, et al. 2001. Intraoral chilling versus 
oral sumatriptan for acute migraine. Heart Dis, 3:357–61.
Gargus JJ. 2006. Ion channel functional candidate genes in multigenic 
neuropsychiatric disease. Biol Psychiatry, 60:177–85.
Goadsby PJ. 2005. Migraine pathophysiology. Headache, 45(Suppl.1):
S14–S24.
Grond S, Sablotzki A. 2004. Clinical pharmacology of tramadol. Clin 
Pharmacokinet, 43:879–923.
Hadjikhani N, Sanchez Del Rio M, Wu O, et al. 2001. Mechanisms of 
migraine aura revealed by functional MRI in human visual cortex. Proc 
Natl Acad Sci U S A, 98:4687–92.
Heydenreich A. 1988. (Punctate transcutaneous electrical nerve stimula-
tion in migraine therapy) (Article in German). Psychiatr Neurol Med 
Psychol (Leipz), 40:717–23.
Hilaire ML, Cross LB, Eichner SF. 2004. Treatment of migraine headaches 
with sumatriptan in pregnancy. Ann Pharmacother, 38:1726–30
Iovino M, Feifel U, Yong C-L, et al. 2004. Safety, tolerability and pharma-
cokinetics of BIBN4096 BS, the ﬁ  rst selective small molecule calcitonin 
gene-related peptide receptor antagonist, following single intravenous 
administration in healthy volunteers. Cephalalgia, 24:645–56.
Karli N, Zarifoglu M, Calisir N, et al. 2005. Comparison of pre-headache 
phases and trigger factors of migraine and episodic tension-type head-
ache: do they share similar clinical Pathophysiology? Cephalalgia, 
25:444–51.
Kaube H, Herzog J, Kaufer T, et al. 2000. Aura in some patients with 
familial migraine can be stopped by intranasal ketamine. Neurology, 
55:139–41.
Kelman L. 2004. The premonitory symptoms (prodrome): a tertiary care 
study of 893 migraineurs. Headache, 44:865–872.
Kelman L. 2005. The postdrome of the acute migraine attack. Cephalalgia, 
26:214–220.
Keskinbora K, Aydinli I. 2006. (An atypical Opioid analgesic: Tramadol.) 
(Article in Turkish) Agri, 18:5–19.
Kirchmann N. 2006. Migraine with aura: new understanding from clinical 
epidemiologic studies. Curr Opin Neurol, 19:286–93.
Kors E, Hann J, Ferrari M. 2003. Migraine genetics. Curr Pain Headache 
Rep, 7:212–17.
Krymchantowski AV, Bigal ME. 2004. Rizatriptan versus rizatriptan plus 
rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment 
of migraine. BMC Neurol, 4:10–16.
Krymchantowski AV, Bigal ME, Moreira PF. Rizatriptan versus rizatriptan 
plus trimebutine for the acute treatment of migraine: A double-blind, 
randomized, cross-over, placebo controlled study. Presented as a poster 
presentation at the AAN meeting in April 2005 at Miami Beach, Fl.
Landy SH. 2004. Oral transmucosal fentanyl citrate for the treatment 
of migraine headache pain in outpatients: a case series. Headache, 
44:762–6.
Landy SH, McGinnis JE, McDonald SA. 2005. Pilot study evaluating 
preference for 3-mg versus 6-mg subcutaneous sumatriptan. Headache, 
45:346–9.
Lashley KS. 1941. Patterns of cerebral integration indicated by scotomas 
of migraine. Arch Neurol Psych, 46:331–9.
Leão AAP. 1944. Spreading depression of activity in the cerebral cortex. J 
Neurophysiol, 7:359–90.Therapeutics and Clinical Risk Management 2007:3(3) 459
Acute migraine treatment
Leniger T, Pageler L, Stude P, et al. 2005. Comparison of intravenous 
valproate with intravenous lysine-acetylsalicylic acid in acute migraine 
attacks. Headache, 45:42–6.
Lipton RB, Stewart WF, Diamond S, et al. 2001a. Prevalence and burden of 
migraine in the United States: data from the American Migraine Study 
II. Headache, 41:646–57
Lipton RB, Diamond S, Reed M, et al. 2001b. Migraine diagnosis and 
treatment: results from the American Migraine Study II. Headache, 
41:638–45.
Lipton RB, Scher AI, Kolodner K, et al. 2002. Migraine in the United 
States - epidemiology and patterns of health care use. Neurology, 
58:885–894.
Lipton RB, Bigal ME. 2005. Migraine epidemiology, impact, and risk fac-
tors for progression. Headache, 45(Suppl.1):S3–S13
Lipton RB, Goldstein J, Baggish JS, et al. 2005. Aspirin is Efﬁ  cacious for 
the treatment of acute migraine. Headache, 45:283–92
Loder E. 2001. Menstrual migraine. Curr Treat Options Neurol, 
3:189–200.
Loder E. 2005. Post-marketing experience with an opioid nasal spray for 
migraine: lessons for the future. Cephalalgia, 26:89–97.
Luciani R, Carter D, Mannix L, et al. 2000. Prevention of migraine during 
prodrome with naratriptan. Cephalagia, 20:122–126. 
Mannix LK, Files JA. 2005. The use of triptans in the management of 
menstrual migraine. CNS Drugs, 19:951–72.
Marcus DA, Scharff L, Turk D, et al. 1997. A double-blind provocative study 
of chocolate as a trigger of headache. Cephalagia, 17:855–62.
Melchart D, Thormaehlen J, Hager S, et al. 2003. Acupuncture versus 
placebo versus sumatriptan for early treatment of migraine attacks: a 
randomized controlled trial. J Intern Med, 253:181–8.
Mellick LB, Mellick GA. 2004. Treatment of primary headache in the 
emergency department. Headache, 44:840–1.
Morillo LE, Alarcon F, Aranaga N, et al. 2005. Clinical Characteristics and 
Patterns of Medication Use of Migraineurs in Latin America from 12 
Cities in 6 Countries. Headache, 45:118–126.
Newman, et al. 2002. Poster presented at: The Diamond Headache Clini-
cal Research and Educational Foundation Meeting, July 16–20, 2002, 
Lake Buena Vista, FL.
Peroutka SJ. 1997. Dopamine and migraine. Neurology, 49:650–656.
Pfaffenrath V, Rehm M. 1998. Migraine in pregnancy. What are the safest 
treatment options? Drug Safety Concepts, 19:383–8.
Pryse-Phillips WEM, Dodick DW, Edmeads JG, et al. 1998. Guidelines for 
the non-pharmacologic management of migraine in clinical practice. 
CMAJ, 159:47–54.
Ramadan NM. 2005. Targeting therapy for migraine: what to treat? Neurol-
ogy, 64(Suppl.2):S4–S8
Reiter PD, Nickisch J, Merritt G. 2005. Efﬁ  cacy and Tolerability of 
Intravenous Valproic Acid in Acute Adolescent Migraine. Headache, 
45:899–903.
Robbins L. 1989. Cryotherapy for headache. Headache, 29:598–600.
Romoli M, Allais G, Airola G, et al. 2005. Ear acupuncture in the control 
of migraine pain: selecting the right acupoints by the “needle-contact 
test”. Neurol Sci, 26 Suppl2:s158–161.
Rothrock JF. 2006. Headache toolbox: headache diary. Headache, 
46:831–832.
Rozen T. 2004. Migraine prodrome: a nose on a face. Lancet, 363:517.
Russell MB, Rasmussen BK, Fenger K, et al. 1996. Migraine without aura 
and migraine with aura are distinct clinical entities: a study of four 
hundred and eighty-four male and female migraineurs from the general 
population. Cephalalgia, 16:239–245.
Sang CN, Ramadan NM, Wallihan RG, et al. 2004. LY293558, a novel 
AMPA/GluR5 antagonist, is efﬁ  cacious and well tolerated in acute 
migraine. Cephalalgia, 24:596–602.
Saper JR, 1997. Diagnosis and symptomatic treatment of migraine. Head-
ache, 37(Suppl 1):S1–S14.
Schwartz, Tamara H, Karpitski Y, et al. 2002. Intravenous Valproate Sodium 
in the Treatment of Daily Headache. Headache, 42:519–522.
Silberstein SD 1993. Headaches and women: treatment of the pregnant and 
lactating migraineur. Headache, 33:533–540.
Silberstein SD. 2000. Practice parameter: Evidence-based guidelines for 
migraine headache (an evidence-based review): Report of the Quality 
Standards Subcommittee of the American Academy of Neurology. 
Neurology, 55:754–62.
Silberstein SD, Lipton RB, Goadsby PJ. 2002. Migraine: Diagnosis and 
treatment. In: Headache in clinical practice, 2nd Edition, Martin Dunitz 
Ltd, London, United Kingdom, p 76.
Silberstein SD. 2004. Migraine pathophysiology and its clinical implications. 
Cephalalgia, 24(Suppl.2):2–7
Stewart WF, Lipton RB & Simon D. 1996. Work-related disability: results 
from the American Migraine Study. Cephalalgia, 16:215–85
Stillman MJ, Zajac D, Rybicki LA. 2004. Treatment of primary headache 
disorders with intravenous valproate: initial outpatient experience. 
Headache, 44:65–9
Ta LE, Dionne RA, Friction JR, et al. 2000. SYM-2081 a kainate receptor 
antagonist reduces allodynia and hyperalgesia in a freeze injury model 
of neuropathic pain. Brain Res, 858:106–20.
Takeshima T, Nakashima K. 2005. (Genetic análisis of migraine headache: 
a review) (Article in Japanese) Nipón Rinsho, 63:1727–32.
Tepper SJ, Rappaport A, Sheftell F. 2001. The pathophysiology of migraine. 
The Neurologist, 7:279–286.
Tepper SJ, Dahlof CGH, Dowson A, et al. 2004. Prevalence and diagnosis 
of migraine patients consulting their physician with a complaint of 
headache: data from the Landmark study. Headache, 44:856–864. 
The International Classiﬁ  cation of Headache Disorders 2nd edition. 2004. 
Cephalagia, 24(Suppl 1):1–160.
Thomsen LL, Olesen J. 2004. Sporadic hemiplegic migraine. Cephalagia, 
24:1016–23.
Villalón CM, Centurion D, Valdivia LF, et al. 2003. Migraine: patho-
physiology, pharmacology, treatment and future trends. Curr Vasc 
Pharmacol, 1:71–84.
Waeber C, Moskowitz M. 2005. Migraine as an inﬂ  ammatory disorder. 
Neurology, 64(Suppl.2):S9–S15.
Weiller C, May A, Limmroth V, et al. 1995. Brainstem activation in spon-
taneous human migraine attacks. Nat Med, 1:658–60.
Welch KM, Nagesh V, Aurora SK, et al. 2001. Periaqueductal gray matter 
dysfunction in migraine: cause or the burden of illness? Headache, 
41:629–37.
Welch KMA. 2003. Contemporary concepts of migraine pathogenesis. 
Neurology, 61(Suppl 4): S2–S8.